Thursday, October 10, 2013 3:43:11 PM
AngioDynamics Signs Multi-Year, Sole-Source Agreement With Large Integrated Delivery Network Group
11:51 AM ET 10/10/13 | GlobeNewswire
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced that it has signed a sole-source, three-year port product agreement with the Large Integrated Delivery Network Group (LIDN) - a group formed by eight IDNs from large Premier, Inc. member healthcare systems, including Adventist Health, Carolinas Healthcare System, Fairview Health System, Henry Ford Health System, Methodist Health System, Norton Healthcare, Park Nicollet, and Texas Health Resources, in order to transform supply chain services.
"The comprehensiveness of our Vascular Access product line following the Navilyst transaction has allowed us to execute a strategy focused on deeper penetration of GPOs and IDNs," said Joseph M. DeVivo, President and CEO of AngioDynamics. "The LIDN's choice of our ports illustrates the promise in this opportunity, demonstrating our ability to increase our patient and product volume by capitalizing on opportunities to gain momentum in the U.S."
Under the terms of the agreement, effective November 1, 2013, AngioDynamics' entire port line, including its new BioFlo Ports, will be available to approximately 130 hospitals in the group that utilize ports. Annually, LIDN Members accounts for approximately $3.8 billion in healthcare spend, with up to $4 million being spent specifically on implantable ports.
"We are pleased to bring value to the LIDN and its member companies by offering our quality port products, including our recently FDA-cleared BioFlo ports," said Scott Centea, AngioDynamics' Director of Corporate Accounts. "Featuring Endexo technology, BioFlo ports are designed to reduce the accumulation of catheter-related thrombus on, and in, the port catheter, highlighting the innovative technologies in our comprehensive port portfolio."
About AngioDynamics
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
Trademarks
AngioDynamics, the AngioDynamics logo, BioFlo and Navilyst are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Endexo is a trademark of Interface Biologics.
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2013. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
View data
CONTACT: Company Contact: AngioDynamics, Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com Investor Relations Contacts: EVC Group, Inc. Michael Polyviou/Robert Jones (212) 850-6020; (646) 201-5447 mpolyviou@evcgroup.com; bjones@evcgroup.com Media Contact: EVC Group, Inc. Nicole Kruse (212) 850-6025 nkruse@evcgroup.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwNTIxNDYjMTY5MTQ=
Recent ANGO News
- US Index Futures Rise, Oil Dips Slightly • IH Market News • 04/04/2024 11:31:45 AM
- AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture • Business Wire • 04/04/2024 11:00:00 AM
- AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE • Business Wire • 04/04/2024 10:45:00 AM
- AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc. • Business Wire • 04/01/2024 09:26:00 PM
- AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024 • Business Wire • 03/19/2024 08:01:00 PM
- AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference • Business Wire • 03/06/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:49:30 AM
- AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million • Business Wire • 02/15/2024 09:05:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/23/2024 09:14:00 PM
- AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease • Business Wire • 01/23/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 12:30:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 12:30:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/08/2024 09:47:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 12:15:29 PM
- AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance • Business Wire • 01/05/2024 12:00:00 PM
- AngioDynamics to Present at the J.P. Morgan Healthcare Conference • Business Wire • 12/21/2023 09:01:00 PM
- AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024 • Business Wire • 12/07/2023 09:01:00 PM
- AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism • Business Wire • 12/07/2023 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/07/2023 01:03:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/05/2023 09:15:12 PM
- Wednesday’s Wall Street Highlights: Apple, Intel, Cal-Maine, A10 Networks, and more • IH Market News • 10/04/2023 11:22:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 11:15:31 AM
- AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance • Business Wire • 10/04/2023 11:00:00 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 09/22/2023 01:28:56 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM